Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Exelon & HUGE GROWING UNMET NEED
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 01, 2021 2:23pm
74 Views
Post# 33304183

RE:RE:RE:RE:RE:RE:Exelon & HUGE GROWING UNMET NEED

RE:RE:RE:RE:RE:RE:Exelon & HUGE GROWING UNMET NEED
schocor wrote: While I disagree with your narrative, it is prudent to ask you what you believe to be a better investment in the healthcare/rnerspitkcs space. Thanks 


Haha ... Chi-Chi and friends only see the wall in front of them and don't see the garden on the other side.  Therefore the world must be a prison        : )

The further we go, the more GUD looks like PLB but at a bigger scale - with developments being much faster (from a revenue perspective).

---------------------

Note:  updated GUD presentation for tomorrow's conference call at Jefferies. 
     - Exelon has been added to the portfolio. 
     - Novartis has been added as a partner.

Novartis as a partner has huge potential for GUD.  IMO.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities